secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001564590-22-028595
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics Q2 2022 net loss $27.4M; cash $246.3M; IND accepted for CDK4/6 inhibitor PRT3645
--------------------------------------------------------------------------------

- Net loss $27.4M ($0.58/share) vs $26.9M ($0.58/share) Q2 2021; R&D declined $1.1M to $21.3M.
- Cash, equivalents, and marketable securities $246.3M as of June 30, 2022; funds operations into H2 2024.
- FDA accepted IND for brain-penetrant CDK4/6 inhibitor PRT3645; Phase 1 to begin Q4 2022 in multiple cancers.
- PRMT5 (PRT811) expansion cohort data readout and next steps expected H2 2022; MCL1 combo data by end of 2022.
- SMARCA2/BRM degrader program on track to file IND by year-end 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000156459022028595/0001564590-22-028595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000156459022028595/prld-8k_20220809.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-028595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer